Psychedelics Firm Optimind Pharma Sustains Growth Plan Rollout With New Acquisition
Psychedelics therapy provider Optimind Pharma Corp. entered into an acquisition agreement with Wolf Acquisitions 1.0 Corp., an arm's length private British Columbia corporation with investments in the psychedelics industry and one of its wholly-owned subsidiaries.
